|
|
|
European Biopharmaceutical Review
|
Personalised medicine means that medical treatment can be tailored towards an individual after a disease has been – hopefully correctly – diagnosed. The treatment should take multiple factors such as age, weight, lifestyle, and, ultimately, genomic information into account. The more precisely and reliably this can be done, the better the patient should respond to the therapy without any unwanted adverse effects.
Nowadays, the term ‘personalised medicine’ is almost exclusively associated with next generation sequencing (NGS) or whole genome sequencing (WGS), respectively. This means one essentially takes a sample (a simple stick in the mouth serves this purpose well) and sends it to their favourite NGS company, which will probably cost less than €1,000, and then they get a long list of diseases and a probability that they will develop one of these diseases or they already have one or multiple diseases. However, that is not the whole story, and, probably, the more interesting story starts there.
A Brief History of WGS
At the beginning in 1990, sequencing the entire human genome for the first time took 13 years and $3 billion. Nine years later, 69 more human genomes were sequenced. In 2016, the University of Toronto launched a project to sequence 10,000 genomes within one year (1). As of the beginning of 2018, the 100,000 genomes project has reached almost 40,000 sequenced genomes and is expected to reach its goal by end of the same year (2). When you look at the cost for sequencing a genome (see Figure 1, page 54, noting the logarithmic y-scale), it becomes clear what a tremendous progress the whole technique has made over the past few years. |
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
News and Press Releases |
 |
Dempsey Demystifies Regulatory Cycle at DIA Europe
March 22, 2018 (Hartford, Conn.) – RWS Life Sciences Managing Director,
Sheena Dempsey, will present “Demystifying the Multilingual Complexities
in the Regulatory Cycle” at DIA Europe 2018, on April 17, at 3:30PM
(CET), in Basel, Switzerland.
More info >> |
|
 |
White Papers |
 |
|
Tightening Your Supply Chain Against Counterfeits
World Courier
As today’s global pharmaceutical supply chain grows increasingly longer and more complex, each link provides added opportunity for counterfeiters.
While pending regulatory changes promise to tighten the supply chain with respect to production and distribution entities and new packaging technologies will make the identification of counterfeit products easier, the logistics of global distribution remains a weak link.
How can the pharmaceutical shipper ensure the security of the supply chain over thousands of miles and extended periods of time when the product is no longer in his possession?
More info >> |
|
 |
Industry Events |
 |
ChinaBio Partnering Forum 2018
25-26 April 2018, Kempinski Hotel Suzhou, Jiangsu, China
Access a world of opportunities through life science
partnering in China. ChinaBio® Partnering Forum is the premier
life science partnering event in China. The conference will be held April 25–26 in Suzhou,
attracting biotech and pharma leaders from around the world along with hundreds
of China-based developers of novel technologies for two days of productive
partnering.
More info >> |
|
|
